Opioid-induced neurotoxicity after opioid conversion to methadone in patients with cancer pain using the stop-and-go method: A multicenter retrospective cohort study


Por: Calsina-Berna, A, González-Barboteo, J, Esteve, A, Torromé, SL, Juarros, GS, Pérez, MB, Miranda, IC, Pardo, MA, Mendoza, LN, Ballart, PG, Cuadros-Margarit, R, Plaza, MO, Sequeiros, CAC, Trias, ML, Cuenca-Casbas, P, Bavestrello, P, Rodrigo, MA, Roda, IB and Julià-Torras, J

Publicada: 11 ene 2026
Resumen:
Purpose To describe the frequency of opioid-induced neurotoxicity (OINT) after opioid conversion (OC) to methadone using the Stop-and-Go (SAG) method in cancer patients with inadequate pain control, and to identify factors associated with OINT. Methods This multicenter retrospective cohort study included adult hospitalized cancer patients who underwent OC to methadone using the SAG method for poor pain control at two comprehensive cancer centers between January 2018 and October 2022. Patients were monitored 14 days after OC, and variables related to OINT were analyzed. Ethical approval was obtained. Results A total of 372 patients underwent OC using the SAG method. The mean morphine-equivalent daily dose (MEDD) before OC was 212.2 mg (SD 128). OINT occurred in 70 patients (18.8%). Methadone was permanently discontinued in 2 patients (2.8%) and temporarily withheld in 7, while 61 were managed with hydration and a 15-20% methadone dose reduction. No patient required naloxone. OINT was less frequent in younger patients (mean age 59.4 vs. 63 years; p = 0.032) and showed a trend toward lower incidence in women (13% vs.22%; p = 0.065). Preexisting cognitive impairment or delirium was associated with OINT (52.4% vs.16.8%; p < 0.001). The mean time from OC to death was shorter among patients with OINT (2.1 months; SD 3.9) compared with those without OINT (3.6 months; SD 6.4; p = 0.012). Conclusion OC to methadone using the SAG method in patients with low-to-moderate MEDD was associated with a relatively low OINT frequency (18.8%). These findings suggest that SAG method in patients with low-to-moderate MEDD before OC may be safe, particularly for younger patients and those without cognitive impairment.

Filiaciones:
Calsina-Berna, A:
 Inst Catala Oncol Badalona, Catalan Inst Oncol GRICOPAL, Res & Knowledge Grp Palliat Care, Palliat Care Dept, Badalona, Spain

 Univ Vic Cent Univ Catalonia UVic UCC, Fac Med, Manresa, Catalonia, Spain

González-Barboteo, J:
 Univ Vic Cent Univ Catalonia UVic UCC, Fac Med, Manresa, Catalonia, Spain

:
 Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol ICO, Med Oncol Serv,IGTP, Badalona Appl Res Grp Oncol,B ARGO CARE Program, Badalona, Spain

Torromé, SL:
 Inst Catala Oncol Hosp, Res & Knowledge Grp Palliat Care Catalan Inst Onco, Palliat Care Dept, Barcelona, Spain

Juarros, GS:
 Inst Catala Oncol Hosp, Res & Knowledge Grp Palliat Care Catalan Inst Onco, Palliat Care Dept, Barcelona, Spain

Pérez, MB:
 Inst Catala Oncol Badalona, Palliat Care Dept, Badalona, Spain

Miranda, IC:
 Consorci Sanit Terrassa, Anesthesiol Dept, Terrassa, Spain

Pardo, MA:
 Inst Catala Oncol Badalona, Palliat Care Dept, Badalona, Spain

Mendoza, LN:
 Inst Catala Oncol Badalona, Palliat Care Dept, Badalona, Spain

Ballart, PG:
 Inst Catala Oncol Badalona, Palliat Care Dept, Badalona, Spain

Cuadros-Margarit, R:
 Inst Catala Oncol Hosp, Res & Knowledge Grp Palliat Care Catalan Inst Onco, Palliat Care Dept, Barcelona, Spain

Plaza, MO:
 Inst Catala Oncol Hosp, Res & Knowledge Grp Palliat Care Catalan Inst Onco, Palliat Care Dept, Barcelona, Spain

Sequeiros, CAC:
 Inst Catala Oncol Hosp, Res & Knowledge Grp Palliat Care Catalan Inst Onco, Palliat Care Dept, Barcelona, Spain

Trias, ML:
 Inst Catala Oncol Hosp, Res & Knowledge Grp Palliat Care Catalan Inst Onco, Palliat Care Dept, Barcelona, Spain

Cuenca-Casbas, P:
 Inst Catala Oncol Badalona, Palliat Care Dept, Badalona, Spain

Bavestrello, P:
 Inst Catala Oncol Hosp, Res & Knowledge Grp Palliat Care Catalan Inst Onco, Palliat Care Dept, Barcelona, Spain

Rodrigo, MA:
 Inst Catala Oncol Badalona, Pharm Unit, Badalona, Spain

Roda, IB:
 Inst Catala Oncol Badalona, Palliat Care Dept, Badalona, Spain

Julià-Torras, J:
 Univ Int Catalunya, Sch Med & Hlth Sci, Barcelona, Spain

 Inst Catala Oncol Badalona, Palliat Care Dept, Badalona, Spain
ISSN: 14337339





Supportive Care in Cancer
Editorial
Springer Verlag, ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES, Alemania
Tipo de documento: Article
Volumen: 34 Número: 2
Páginas:
WOS Id: 001659029700001
ID de PubMed: 41520030

MÉTRICAS